Literature DB >> 21764781

Seven days of doxycycline is an effective treatment for asymptomatic rectal Chlamydia trachomatis infection.

A Elgalib1, S Alexander, C Y W Tong, J A White.   

Abstract

There are no evidence-based guidelines for the specific management of rectal Chlamydia trachomatis (CT) infection. All men who have sex with men (MSM) diagnosed with asymptomatic rectal CT by nucleic acid amplification test (NAAT) at a large London genitourinary (GU) medicine clinic between September 2006 and September 2009 were offered oral doxycycline 100 mg twice daily for seven days and invited for a test of cure (TOC) by CT NAAT four weeks after treatment. A total of 487 asymptomatic rectal CT infections were diagnosed and analysis was restricted to 165 TOCs from men whose only treatment had been doxycycline for seven days. The median time post-treatment for TOC was 45 days (interquartile range [IQR], 34-88). Only two patients tested CT-positive at follow-up. One had taken doxycycline only for three days; the other attended for TOC 240 days after the completion of doxycycline treatment and at this time presented with new symptoms in the context of ongoing high sexual risk. Our findings show that doxycycline 100 mg twice daily for seven days is highly effective treatment for asymptomatic rectal CT infection, achieving clearance of CT in 98.8% (163/165; 95% CI 95.4-99.9%) of cases. We advocate doxycycline for seven days as first-line therapy for asymptomatic rectal CT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764781     DOI: 10.1258/ijsa.2011.011134

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  7 in total

Review 1.  The growing epidemic of sexually transmitted infections in adolescents: a neglected population.

Authors:  Chelsea L Shannon; Jeffrey D Klausner
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

2.  Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study.

Authors:  Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

3.  High prevalence of rectal gonorrhea and Chlamydia infection in women attending a sexually transmitted disease clinic.

Authors:  Jose A Bazan; Patricia Carr Reese; Allahna Esber; Samantha Lahey; Melissa Ervin; John A Davis; Karen Fields; Abigail Norris Turner
Journal:  J Womens Health (Larchmt)       Date:  2015-02-18       Impact factor: 2.681

4.  High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women.

Authors:  Geneviève A F S van Liere; Christian J P A Hoebe; Petra F G Wolffs; Nicole H T M Dukers-Muijrers
Journal:  BMC Infect Dis       Date:  2014-05-19       Impact factor: 3.090

Review 5.  Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature.

Authors:  Philip A Chan; Ashley Robinette; Madeline Montgomery; Alexi Almonte; Susan Cu-Uvin; John R Lonks; Kimberle C Chapin; Erna M Kojic; Erica J Hardy
Journal:  Infect Dis Obstet Gynecol       Date:  2016-06-05

6.  Design of the FemCure study: prospective multicentre study on the transmission of genital and extra-genital Chlamydia trachomatis infections in women receiving routine care.

Authors:  Nicole H T M Dukers-Muijrers; Petra F G Wolffs; Lisanne Eppings; Hannelore M Götz; Sylvia M Bruisten; Maarten F Schim van der Loeff; Kevin Janssen; Mayk Lucchesi; Titia Heijman; Birgit H van Benthem; Jan E van Bergen; Servaas A Morre; Jos Herbergs; Gerjo Kok; Mieke Steenbakkers; Arjan A Hogewoning; Henry J de Vries; Christian J P A Hoebe
Journal:  BMC Infect Dis       Date:  2016-08-08       Impact factor: 3.090

7.  Orolabial Lymphogranuloma Venereum, Michigan, USA.

Authors:  Sahrish Ilyas; Deborah Richmond; Gerald Burns; Katherine E Bowden; Kimberly Workowski; Ellen N Kersh; Pranatharthi H Chandrasekar
Journal:  Emerg Infect Dis       Date:  2019-11       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.